Cadila Pharmaceuticals, a research-driven pharmaceutical companies, has announced the launch of Dlorfast-M Tablets, a new fixed-dose combination therapy containing Desloratadine (5 mg) and Montelukast (10 mg). The innovative dual-action formulation is designed for the management of allergic rhinitis and urticaria, addressing the growing prevalence of allergic disorders in India.
Allergic rhinitis and urticaria are chronic conditions affecting millions worldwide, leading to symptoms such as sneezing, nasal congestion, itching, hives, and swelling. These conditions significantly impact productivity and quality of life. In India, allergy cases have increased due to factors like pollution, lifestyle changes, and genetic predisposition.
Recognising the need for better treatment options, Cadila Pharmaceuticals has introduced Dlorfast-M as a dual-action therapy targeting two major pathways of allergic response histamine and leukotriene.
Desloratadine, a potent histamine H₁-receptor antagonist, blocks histamine-mediated reactions such as itching and swelling. Montelukast, a leukotriene receptor antagonist, prevents airway inflammation and smooth muscle contraction. Together, they offer comprehensive and synergistic relief superior to monotherapy approaches.
Clinical evaluations have demonstrated that the Desloratadine-Montelukast combination provides significant improvement in respiratory allergic symptoms. The once-daily tablet enhances patient compliance and long-term tolerability, making it suitable for adults and adolescents.
Commenting on the launch, Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals Limited, said, “With the launch of Dlorfast-M, Cadila Pharmaceuticals continues its mission to provide accessible, effective, and innovative therapies. This dual-action formulation addresses both histamine and leukotriene pathways, offering superior symptom control and improving quality of life for people living with allergies.” |
